Price
No data yet.
Social Signal Score
Analyst Ratings
21 analystsRevenue
$99.31MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Frederick G. Vogt
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 975
- Beta
- 0.70
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 16.54
Financials
Revenue
$99.31M+41628.2%Net Income
$-47.31MEBITDA
$-39.19MFree Cash Flow
$-66.28MEPS (diluted)
$-0.11Shares Outstanding (diluted)
450.19M+661.6%Operating Expenses
$63.93MCash & Debt
$297.67MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $263.50M | $-390.98M | $-1.09 |
| 2024 | $164.07M | $-372.18M | $-1.28 |
| 2023 | $1.19M | $-444.04M | $-1.89 |
| 2022 | $0.00 | $-395.89M | $-2.49 |
| 2021 | $0.00 | $-342.25M | $-2.23 |
| 2020 | $0.00 | $-259.58M | $-1.88 |
| 2019 | $0.00 | $-197.56M | $-1.50 |
| 2018 | $0.00 | $-123.58M | $-1.27 |
| 2017 | $0.00 | $-92.06M | $-1.41 |
| 2016 | $0.00 | $-52.89M | $-0.96 |
| 2015 | $0.00 | $-27.66M | $-0.62 |
| 2014 | $0.00 | $-12.04M | $-0.48 |
| 2013 | $0.00 | $-25.38M | $-2.60 |
| 2012 | $0.00 | $-3.31M | $-4.14 |
Valuation
IOVAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
40-48.39%Social Signal Score
Mentions (16)
- Newsseekingalpha.com·1d ago·Negative
Iovance: Buy Now Before Many Growth Catalysts Kick In Iovance raised 2026 revenue guidance to $410–$420 million as Amtagvi adoption accelerates, supported by expanding treatment access, greater physician awareness, and faster manufacturing. Frontline melanoma trials, lung cancer development, and international expansion could broaden Amtagvi's market by at least an order of magnitude from the current peak sales expectation of $1B. Internal manufacturing supports improving margins and narrowing lo
View source ↗ - News (Marketaux)insidermonkey.com·2d ago·Positive
Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3 Iovance Biotherapeutics</em[+228 characters]
View source ↗ - Newszacks.com·5d ago·Positive
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 Iovance hits a 52-week high after raising its 2026 revenue outlook to $410-$420 million on strong demand for its marketed therapies.
View source ↗ - Newszacks.com·6d ago·Positive
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - News (RSS)seekingalpha·6d ago·Neutral
Iovance: The Turnaround Is Priced In, Downgrading To Hold
View source ↗ - Newsbenzinga.com·6d ago·Neutral
Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares are trading higher on Tuesday as the company raises full-year 2026 revenue guidance, bucking a -0.8% slide in the Healthcare sector even as the S&P 500 is down 0.10%.
View source ↗ - News (RSS)zerohedge·6d ago·Neutral
…fuel cell maker with a recommendation of outperform, expecting demand to stay “well ahead” of supply as it ramps up its production capacity. Iovance Biotherapeutics (IOVA) climbs 5% after boosting its revenue guidance for the full year. Monday.com Ltd. (MNDY) slips 1.8% after JPMorgan downgraded the software company to neutral from overweight, citing growth challenges for annual recurring revenue. Netflix (NFLX) inches 1% higher after Deutsche Bank upgraded the streaming-video company to buy, sa…
View source ↗ - News (RSS)investing·6d ago·Neutral
Why is Iovance Biotherapeutics stock surging today?
View source ↗ - Newsglobenewswire.com·7d ago·Positive
…Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleuki…
View source ↗ - Newsfool.com·11d ago·Positive
Why Iovance Biotherapeutics Stock Was on Fire Today Happily for investors, it flagged the biotech's shares as a buy. Goldman believes they have nearly 40% upside.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…apeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 17, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Iovance Biotherapeutics to Present at Upcoming Conferences SAN CARLOS, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…rapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an…
View source ↗ - Newsbenzinga.com·45d ago·Neutral
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.
View source ↗ - Newsbenzinga.com·46d ago·Neutral
Why Iovance Biotherapeutics Stock Hit 52-Week High Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having no news to justify the move. Year to date, the stock has surged over 200%.
View source ↗ - Newsseekingalpha.com·46d ago·Neutral
…atalysts Ahead, And Competitor Updates Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.09 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.11 vs $-0.13beat
- Thu, May 7$-0.19 vs $-0.19beat
- Tue, Feb 24$-0.18 vs $-0.22beat
- Thu, Nov 6$-0.25 vs $-0.29beat
- Thu, Aug 7$-0.33 vs $-0.29miss
- Thu, May 8$-0.36 vs $-0.25miss
Estimates and results for IOVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IOVA officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IOVA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.